سعر Prevaglip Plus 2.5/500 mg tablets 2023

Fixed-dose combination of linagliptin 2.5 mg and metformin 500 mg tablets for type 2 diabetes, box of 30, by Eva Pharma, Egypt.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (not for type 1 diabetes)Population: AdultsDailyMed (U.S. National Library of Medicine)

• Serious adverse reactions include lactic acidosis, pancreatitis, hypoglycemia with insulin or secretagogues, hypersensitivity reactions and vitamin B12 deficiency.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR below 30 mL/min/1.73 m2).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to linagliptin, metformin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metformin-associated lactic acidosis (postmarketing cases with death, hypothermia, hypotension and resistant bradyarrhythmias).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Pancreatitis, hypoglycemia with insulin/secretagogues, hypersensitivity, vitamin B12 deficiency, arthralgia, bullous pemphigoid and heart failure are described in the US label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide, dichlorphenamide)May increase the risk of lactic acidosis; consider more frequent monitoring.DailyMed (U.S. National Library of Medicine)

• Limited data with the combination and linagliptin in pregnant women are insufficient to inform drug-associated risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Linagliptin: Inhibits DPP-4, increasing incretin (GLP-1/GIP) levels which enhance glucose-dependent insulin secretion.
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).